$13.63
+0.50 (+3.81%)
Open$13.26
Previous Close$13.13
Day High$13.75
Day Low$13.07
52W High$16.76
52W Low$9.85
Volume—
Avg Volume85.5K
Market Cap463.10M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+97.1% upside
Current
$13.63
$13.63
Target
$26.87
$26.87
$21.20
$26.87 avg
$38.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 792.56M | 838.23M | 726.24M |
| Net Income | 29.18M | 25.09M | 21.12M |
| Profit Margin | 3.7% | 3.0% | 2.9% |
| EBITDA | 33.32M | 33.92M | 33.30M |
| Free Cash Flow | 24.79M | 28.65M | 30.31M |
| Rev Growth | +7.9% | +14.3% | -7.3% |
| Debt/Equity | 0.15 | 0.16 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |